Title: Comparative analysis of treatment options available through the right to try legislation and the expanded access program.

Introduction:

Expanded access approval rate from Pfizer was 98% https://www.pfizer.com/purpose/medicine-access/compassionate-use.

Methods:

Using the Drugs@FDA database I opened the products.txt file through pandas to create a dataframe. Using that generated dataframe I created a list of all unique DrugNames. This gave me a collection of 7088 drugs that the FDA has approved. Then through the clinical trials database I downloaded all drugs listed in interventions for both trails listed as phase 3 that have statuses of either: not yet recruiting, recruiting, enroll by invitation, active not recruiting or suspended (but not including completed) and trails listed as available and/or approved for marketing in their expanded access program. From both these lists I found all unique drug entries and removed all those in the approved drugs@FDA database and those with the text phrase placebo. Because these databases are not linked it’s possible that this does not remove all the approved drugs to contain just the experimental drugs. However, this still provides value as an estimate of what is available.

Using PharmaGKB I downloaded a comprehensive drugs database. From this I created a python program that allowed for me to easily parse their database and query all drugs from Id’s, all Id’s from each drug and all the different terms used for each drug. This was done to create a more compressive list of all terms used for each drug such that one can quickly determine if a drug listed in the warehouse is novel or simply not the main name.

Results:

Discussion:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534121/>

very similar to what I’m doing